56
person
Eileen Murray
person
Deb Liu
Deb Liu is the President and CEO of Ancestry. With over 19 years in the tech industry, she has be
en named one of Business Insider’s most powerful female engineers and one of PaymentsSource’smost influential women in payments.
+ Read More
person
Sébastien Eisinger
staff
Jessica Marshall
Jessica Marshall is an associate at FasterCures.
staff
Nicole Valentine
Nicole Valentine is the director, FinTech at the Milken Institute with over a decade of fina
ncial services, international mergers and acquisitions, technology, and innovation experience.
+ Read More
staff
Christina Dialynas
Christina Dialynas is an associate director at the Milken Institute, Public Health. Prior to join
ing the Center for Public Health, Christina worked on the Milken Institute’s Business and Program Development team as their project manager.
+ Read More
person
Michael Lin, PhD
Dr. Michael Cheng-Yi Lin was a Regional Economist within the Research Department at the Milken In
stitute.
+ Read More
person
Aaron Melaas
report
FinReg21: Modernizing Financial Regulation for the 21st Century
Regulation has a vital role in any financial system—and changes to U.S. financial regulation were c
learly needed in the wake of the financial crisis.
+ Read More
report
Leaving Transferred Money on the Table: Will Remittance-Linked Financial Products Add Value to Development Financing?
For centuries migrant workers who send money home to their families have been a major source of inf
lows for developing countries. However, it is only in the past few decades that we have been able to put a number to these remittances.
+ Read More
report
Financing Green Building in Residential Development
Buildings are responsible for nearly 60 percent of Israel’s electricity consumption and contribute
28 percent of the country’s total greenhouse gas emissions.
+ Read More
report
Policy Issue Brief: A Call to Action for Diversity in Clinical Trials
FasterCures has initiated a body of work to advance system change within biomedical research to foc
us on and value diversity and representation within clinical trials.
+ Read More